The gene expression profile detected in the core needle biopsy of a breast tumour is representative of gene expression in the whole tumour. A study published today in the open access journal Breast Cancer Research confirms the reliability of core needle biopsy as a tool in breast cancer diagnosis and prognosis. The study also shows that the gene expression profile of a core needle biopsy might be more accurate than the profile of a surgical sample taken from the same tumour, after the biopsy was carried out. According to the study results, the biopsy procedure seems to trigger the expression of genes involved in wound healing as well as tumour invasion and metastasis, thus modifying the gene expression profile of subsequent surgical samples.
Rosanna Zanetti-Dllenbach from the Women's University Hospital in Basel, Switzerland and colleagues from Stiftung Tumorbank, OncoScore AG and University Hospital in Basel, analysed the gene expression profile of core needle biopsies taken from 22 women diagnosed with breast cancer. For each woman, they compared the biopsy expression profile with the expression profile of a surgical sample taken from the tumour subsequently to the core needle biopsy. Zanetti-Dllenbach et al. quantified the expression of 60 genes known to be involved in breast tumour development using a technique called reverse polymerase chain reaction (PCR). Zanetti-Dllenbach et al. also analysed the gene expression profiles of surgical samples taken from the breast tumours of 317 patients who did not undergo a core needle biopsy.
The results of Zanetti-Dllenbach et al.'s study show that the gene expression levels of the core biopsy and the surgical sample are identical for most women. But the authors find that the expression of four specific genes is significantly increased in the surgical samples compared to the core needle biopsies. In the group of women who did not get a core needle biopsy, however, the expression of these four genes
Contact: Juliette Savin